The lipid management pathway for secondary prevention of cardiovascular disease has been updated. Changes include:

  • A statement has been added to ensure statin intolerance pathway has a clear emphasis
  • Further highlighting of the position of icosapent ethyl (Vazkepa┬«)
  • Inclisiran option for prescribing has been made clearer

The updated pathway is available on the clinical guidance and pathways page, along with links to other lipid management resources.